Inhibikase 2023 Virtual R&D Event

Inhibikase’s executive leadership team presented key clinical updates and upcoming milestones across the Company’s pipeline during a Virtual R&D day event held March 22, 2023. During the event, management provided an overview of pre-clinical studies that formed the basis for the ongoing Phase 2a '201' trial for IkT-148009 and highlighted the clinical development strategy for the 201 trial as well as future clinical trials evaluating IkT-148009, including its planned expansion into Multiple System Atrophy (MSA). Management also shared the status of IkT-001Pro which is currently being evaluated in a bioequivalence study for Chronic Myelogenous Leukemia. #ParkinsonsDisease #MultipleSystemAtrophy #ChronicMyelogenousLeukemia